1 / 3

Hutchinson-Gilford Progeria Treatment Market Trends Estimates High Demand by 2026

Continuous advancement in research with increased understanding of the human aging will provide valuable insights and aid in the treatment of this disease.

Download Presentation

Hutchinson-Gilford Progeria Treatment Market Trends Estimates High Demand by 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hutchinson-Gilford Progeria Treatment Hutchinson-Gilford Progeria Treatment Market Size, Share, Trend, Outlook, Future Market Size, Share, Trend, Outlook, Future Analysis And Synthesis By 2026 Analysis And Synthesis By 2026 Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a loss of fat under the skin (subcutaneous fat). Moreover, patients of Hutchinson-Gilford progeria syndrome experiences severe hardening of the arteries (arteriosclerosis) from the childhood. The condition worsens with age and increases the risk of heart attack or stroke even at a young age. Download PDF Brochure of Research Report @ Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request- https://www.coherentmarketinsights.com/insight/request- pdf/35 pdf/35 Hutchinson-Gilford progeria is a rare condition that affects about one in four million newborns worldwide according to the National Institutes of Health (NIH). Until now more than 130 cases have been reported as per the NIH statistics. The affected patients live up to 30 years maximum, with an average life span of 13 years. Nearly 90% of the patients die from complications related to atherosclerosis. Till 2012 there wasn’t any effective treatment therapy discovered for Hutchinson-Gilford progeria syndrome. The treatments available focused mostly on reducing cardiovascular symptoms and growth abnormalities. Farnesyltransferase Inhibitor (FTI) Farnesyltransferase Inhibitor (FTI) In 2012, findings of the first clinical trial of the drug Lonafarnib, a farnesyltransferase inhibitor (FTI), gave a new hope for the treatment of children with Hutchinson-Gilford progeria syndrome. Clinical trial results demonstrated improvement in weight gain, increase in bone mineral density, reduced vascular stiffness, and improved sensorineural hearing in patients with progeria. Previous treatments with growth hormone, and Sulforaphane helped in reducing the

  2. symptoms, and prolong a child’s life. However, it is essential that the patient regularly visits the cardiologist. Rapamycin is one other drug used before, that demonstrated to reverse nuclear blebbing, retard cellular senescence, and facilitate degradation of progerin. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Hutchinson-Gilford Progeria Treatment Market Research Objective and Assumption • Hutchinson-Gilford Progeria Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Hutchinson-Gilford Progeria Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Hutchinson-Gilford Progeria Treatment Market, By Regions • Hutchinson-Gilford Progeria Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Hutchinson-Gilford Progeria Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Hutchinson-Gilford Progeria Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Hutchinson-Gilford Progeria Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Recently in 2015, the scientists at the Agency for Science, Technology & Research (A*STAR) successfully established a model of Hutchinson-Gilford progeria syndrome. The study conducted by this organization proposed a model which implies that progerin is linked to telomeres. Progerin induces a reduction in heterochromatin, a tightly packed form of DNA, making telomeres in the cell more fragile and susceptible to damage. The damaged telomeres in turn trigger premature cellular aging. This model is radically different from the one believed earlier – the gene progerin caused the nucleus to be deformed, thereby weakening the ability of cells to divide and proliferate. The altered progerin protein makes the nuclear envelope unstable and progressively damages the nucleus, making cells more likely to die prematurely.

  3. Researchers are working to determine how genetic changes further leading to the characteristic features of Hutchinson-Gilford progeria syndrome. Continuous advancement in research with increased understanding of the human aging will provide valuable insights and aid in the treatment of this disease. Browse Complete Research Report @ Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/hutchinson-gilford-progeria-treatment- https://www.coherentmarketinsights.com/ongoing-insight/hutchinson-gilford-progeria-treatment- market-35 market-35 About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related